高级检索
当前位置: 首页 > 详情页

Traditional Chinese medicine (Xiaoai Jiedu Decoction) as an adjuvant treatment for prevention new colorectal adenomatous polyp occurrence in post-polypectomy Study protocol for a randomized controlled trial

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Affiliated Hospital of Nanjing University of Chinese Medicine, [2]Nanjing University of Chinese Medicine, [3]The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, [4]Guangdong Province Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, [5]Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, [6]Beijing Friendship Hospital, Beijing, [7]Shuguang Hospital Shanghai University of Traditional Chinese Medicine, [8]Changhai Hospital of Shanghai, Shanghai, China.
出处:
ISSN:

关键词: Chinese herbal medicine colorectal adenomatous polyp randomized controlled trial Xiaoai Jiedu decoction

摘要:
Background: Colorectal Adenomatous Polyp (CAP) was one precursor of colorectal cancer (CRC) and having a high chance of developing into CRC. There was a lack of conclusive chemoprevention evidences to prevention new CAP occurrence in post-polypectomy. Xiaoai Jiedu Decoction, Chinese National Medical Professor (Zhou Zhongying)'s experience formula, has been used to treat new CAP occurrence in post-polypectomy from the 20th century in China. However, clinical research of Xiaoai Jiedu Decoction in the treatment of CAP recurrence was lack. We design this study to evaluate the efficacy and safety of Xiaoai Jiedu Decoction in the treatment of new CAP occurrence in post-polypectomy on colonoscopy. Methods/Design: A randomized, controlled, blind and multicenter trial to evaluate the efficacy and safety of Xiaoai Jiedu Decoction is proposed. CAP patients (after complete polypectomy under colonoscopy) will be randomly assigned into Xiaoai Jiedu Decoction group and Xiaoai Jiedu Decoction mimetic agent group. Patients will receive 6-course treatments and a 2-year follow-up. Follow-up colonoscopy will be anticipated to perform in 1 and 2 years after the baseline examinations. The primary outcome measure is the new CAP occurrence in 1 and 2 years. The secondary outcome measure is the occurrence of advanced adenoma in 1 and 2 years. Discussion: This study will provide objective evidences to evaluate the efficacy and safety of Xiaoai Jiedu Decoction as an adjuvant treatment for new CAP occurrence in post-polypectomy.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 3 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2017]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Affiliated Hospital of Nanjing University of Chinese Medicine,
共同第一作者:
通讯作者:
通讯机构: [1]Affiliated Hospital of Nanjing University of Chinese Medicine, [2]Nanjing University of Chinese Medicine, [*1]Nanjing University of Chinese Medicine, Nanjing 210029, China [*2]Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号